Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

BioNTech SE (BNTX) Receives a Buy from Morgan Stanley

Tipranks - Tipranks - Wed Mar 11, 3:30AM CDT

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE yesterday and set a price target of $134.00. The company’s shares closed yesterday at $102.16.

Claim 70% Off TipRanks Premium

Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Moderna, and Pfizer. According to TipRanks, Flynn has an average return of 10.6% and a 58.00% success rate on recommended stocks.

Currently, the analyst consensus on BioNTech SE is a Strong Buy with an average price target of $138.00.

See Insiders’ Hot Stocks on TipRanks >>

Based on BioNTech SE’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.52 billion and a GAAP net loss of $28.7 million. In comparison, last year the company earned a revenue of $1.24 billion and had a net profit of $198.1 million

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.

Read More on BNTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).